

REMARKS

In response to the Restriction Requirement in the Office Action, Applicants hereby elect, with traverse, the invention of Group II (claims 7-8 and 37) drawn to a fusion peptide specifically inhibiting the translation of a target polynucleotide of interest. Applicants further elected the fusion polypeptides of SEQ ID NOS: 5-6 as the elected sequences for examination on the merits.

The traversal is on the grounds that the inventions and the identified sequences are sufficiently closely related that a search and examination of the entire application can be made without a serious burden to the Office. For instance, the sequences of SEQ ID NOS: 5 and 6 are closely related and overlapping in scope. As such, a search and examination of one would necessarily overlap that of the other.

Thus, in view of the above, it is believed that Applicants are entitled to an action on the merits of all pending claims, in their full scope, in the present application.


In the event that the Office disagrees with the traversal and maintains the requirement, then kindly consider the possibility of rejoinder of the non-elected invention, upon a determination of allowance of the elected invention, per U.S. rejoinder practice and M.P.E.P. § 821.04.

Favorable action on the merits is solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON


Jay Williams, Reg. No. 48,036
209 Madison Street, Suite 500
Alexandria, VA 22314
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

JFW/